(1) SCHEDULE I.—
(A) The drug or other substance has a high potential for abuse.
(B) The drug or other substance has no currently accepted medical use in treatment in the United States.
(C) There is a lack of accepted safety for use of the drug or other substance under medical supervision.
(2) SCHEDULE II.—
(A) The drug or other substance has a high potential for abuse.
(B) The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions.
(C) Abuse of the drug or other substances may lead to severe psychological or physical dependence.
(3) SCHEDULE III.—
(A) The drug or other substance has a potential for abuse less than the drugs or other substances in schedules I and II.
(B) The drug or other substance has a currently accepted medical use in treatment in the United States.
(C) Abuse of the drug or other substance may lead to moderate or low physical dependence or high psychological dependence.
4) SCHEDULE IV.—
(A) The drug or other substance has a lowpotential for abuse relative to the drugs or other substances in schedule III.
(B) The drug or other substance has a currently accepted medical use in treatment in the United States.
(C) Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule III.
5) SCHEDULE V.—
(A) The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule IV.
(B) The drug or other substance has a currently accepted medical use in treatment in the United States.
(C) Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule IV.
(6) Schedule VI.-
(A) The drug or other substance is listed in Schedule I.
(B) The drug or other substance is subject to some degree of abuse and has a currently accepted medical use in treatment or is restricted for Sale to Adults over the age of 21 in the States of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Utah, Vermont, Virginia, Washington, West Virginia, the District of Columbia, the Commonwealth of the Northern Mariana Islands, the United States Virgin Islands, Guam, or Puerto Rico.
(C) Drugs grown or manufactured for intrastate Commerce shall be regulated exclusively by the States. All United States Codes, Internal Revenue Codes and any federal agency rules shall be applied exclusively using this schedule for licensed producers of the drug in the States and Territories listed in (B). Licensed producers shall be defined according to the statutes or codes of the States and Territories listed in (B).
(D) Drug regulation and restriction is governed by each State or Territory listed individually in (B). If a State or Territory not listed in (B) legalizes the drug or other substance for medical use in treatment or makes it available for Sale only to adults over the age of 21, the agency regulating the drug in that State or Territory can notify the Attorney General that it is to be added to (B). The Attorney General shall add the State or Territory to (B) within ninety days of notification.